
HBM Healthcare Investments
Overview
Venture capital firm investing in biotechnology and medical technology.
Founded
2001
Deals ยท 12mo
7
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Crystalys Therapeutics | Jul 2026Participated | $130 MSeries B | |
Fore Biotherapeutics | Jul 2026Participated | $67 MSeries D | |
Lycia Therapeutics | Jun 2026Participated | $75 MSeries D | |
CellCentric | May 2026Participated | $220 MSeries D | |
Jixing Pharmaceuticals | Jan 2026Participated | $287 MSeries D | |
Parabilis Medicines | Jan 2026Participated | $305 MSeries F | |
Electra Therapeutics | Oct 2025Participated | $183 MSeries C | |
Neuron23 | Jun 2025Participated | $97 MSeries D | |
Fore Biotherapeutics | May 2025Participated | $38 MSeries D | |
Curevo | Mar 2025Participated | $110 MSeries B | |
Bluejay Therapeutics | May 2024Participated | $182 MSeries C | |
Karius | May 2024Participated | $100 MSeries C | |
Crystalys Therapeutics | Jul 2026Participated | $130 MSeries B | |
Fore Biotherapeutics | Jul 2026Participated | $67 MSeries D | |
Lycia Therapeutics | Jun 2026Participated | $75 MSeries D | |
CellCentric | May 2026Participated | $220 MSeries D | |
Jixing Pharmaceuticals | Jan 2026Participated | $287 MSeries D | |
Parabilis Medicines | Jan 2026Participated | $305 MSeries F | |
Electra Therapeutics | Oct 2025Participated | $183 MSeries C | |
Neuron23 | Jun 2025Participated | $97 MSeries D | |
Fore Biotherapeutics | May 2025Participated | $38 MSeries D | |
Curevo | Mar 2025Participated | $110 MSeries B | |
Bluejay Therapeutics | May 2024Participated | $182 MSeries C | |
Karius | May 2024Participated | $100 MSeries C |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 2 | 6 |
| Series B | 5 | 24 |
| Series C+ | 8 | 36 |
| Other Equity | 3 | 14 |
| Debt | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Aug '07 | 1 |
| Sep '07 | 0 |
| Oct '07 | 0 |
| Nov '07 | 0 |
| Dec '07 | 0 |
| Jan '08 | 0 |
| Feb '08 | 0 |
| Mar '08 | 0 |
| Apr '08 | 0 |
| May '08 | 0 |
| Jun '08 | 0 |
| Jul '08 | 0 |
| Aug '08 | 0 |
| Sep '08 | 0 |
| Oct '08 | 0 |
| Nov '08 | 0 |
| Dec '08 | 1 |
| Jan '09 | 0 |
| Feb '09 | 0 |
| Mar '09 | 0 |
| Apr '09 | 0 |
| May '09 | 0 |
| Jun '09 | 0 |
| Jul '09 | 0 |
| Aug '09 | 0 |
| Sep '09 | 0 |
| Oct '09 | 0 |
| Nov '09 | 1 |
| Dec '09 | 2 |
| Jan '10 | 0 |
| Feb '10 | 0 |
| Mar '10 | 0 |
| Apr '10 | 0 |
| May '10 | 0 |
| Jun '10 | 1 |
| Jul '10 | 0 |
| Aug '10 | 0 |
| Sep '10 | 1 |
| Oct '10 | 0 |
| Nov '10 | 2 |
| Dec '10 | 0 |
| Jan '11 | 0 |
| Feb '11 | 0 |
| Mar '11 | 0 |
| Apr '11 | 0 |
| May '11 | 1 |
| Jun '11 | 0 |
| Jul '11 | 0 |
| Aug '11 | 1 |
| Sep '11 | 0 |
| Oct '11 | 0 |
| Nov '11 | 0 |
| Dec '11 | 0 |
| Jan '12 | 1 |
| Feb '12 | 0 |
| Mar '12 | 0 |
| Apr '12 | 0 |
| May '12 | 0 |
| Jun '12 | 0 |
| Jul '12 | 1 |
| Aug '12 | 0 |
| Sep '12 | 0 |
| Oct '12 | 0 |
| Nov '12 | 0 |
| Dec '12 | 0 |
| Jan '13 | 0 |
| Feb '13 | 0 |
| Mar '13 | 1 |
| Apr '13 | 0 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 0 |
| Aug '13 | 0 |
| Sep '13 | 0 |
| Oct '13 | 0 |
| Nov '13 | 0 |
| Dec '13 | 0 |
| Jan '14 | 0 |
| Feb '14 | 1 |
| Mar '14 | 1 |
| Apr '14 | 0 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 0 |
| Sep '14 | 0 |
| Oct '14 | 0 |
| Nov '14 | 0 |
| Dec '14 | 0 |
| Jan '15 | 1 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 1 |
| Jul '15 | 1 |
| Aug '15 | 0 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 1 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 1 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 1 |
| Jul '16 | 0 |
| Aug '16 | 1 |
| Sep '16 | 0 |
| Oct '16 | 1 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 4 |
| Aug '17 | 2 |
| Sep '17 | 0 |
| Oct '17 | 2 |
| Nov '17 | 0 |
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 1 |
| May '18 | 1 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 2 |
| Oct '18 | 3 |
| Nov '18 | 1 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 2 |
| May '19 | 0 |
| Jun '19 | 1 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 2 |
| Jul '20 | 1 |
| Aug '20 | 1 |
| Sep '20 | 5 |
| Oct '20 | 1 |
| Nov '20 | 2 |
| Dec '20 | 0 |
| Jan '21 | 4 |
| Feb '21 | 0 |
| Mar '21 | 5 |
| Apr '21 | 1 |
| May '21 | 2 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 2 |
| Dec '21 | 3 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 3 |
| Jul '22 | 1 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 1 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 2 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 2 |
| Apr '24 | 0 |
| May '24 | 2 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 1 |
| Apr '25 | 0 |
| May '25 | 1 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 2 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 1 |
| Jul '26 | 2 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 101 |
| Hardware & Robotics | 2 |
| Manufacturing | 2 |
| Enterprise Software | 1 |
| AI & Machine Learning | 1 |
| Professional Services | 1 |
| Social & Community Platforms | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 5 |
| $10M-$25M | 13 |
| $25M-$50M | 14 |
| $50M-$100M | 32 |
| $100M-$250M | 31 |
| $250M-$500M | 6 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 5 of 5 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 75 |
| Europe | 18 |
| China | 5 |
| India | 2 |
| Canada | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Cormorant Asset Management | 26 |
| OrbiMed | 23 |
| RA Capital Management | 16 |
| SR One | 15 |
| Invus | 11 |
| Janus Henderson Investors | 10 |
| T. Rowe Price Associates | 10 |
| Wellington Management | 10 |
| Adage Capital Management | 9 |
| Alexandria Venture Investments | 9 |
| Fidelity Management & Research Company | 9 |
| Novo Holdings | 9 |
| RTW Investments | 9 |
| Samsara BioCapital | 9 |
| Google Ventures | 8 |
| Logos Capital | 8 |
| Novartis | 8 |
| Rock Springs Capital | 8 |
| venBio Partners | 8 |
| Foresite Capital | 7 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 19 | 19% |
| Participating | 82 | 81% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 9 | 47% |
| Co-led | 10 | 53% |
Team
Secretary to the Board
Chairman, Board of Directors
Vice Chairman,Board of Directors and Member of the Audit Committee
Member of the Board of Directors
Member of the Board of Directors